Table 1 Characteristics of included studies
Study | NCT number | SGLT2 inhibitor | Background therapy | Sample size | Male (%) | Mean Age (year) | Mean HbA1c (%) | Mean BMI (kg/m²) | Follow up (weeks) |
|---|---|---|---|---|---|---|---|---|---|
Bolinder et al. (2014) [11] | NCT00855166 | DAPA: 10Â mg | MET | 180 | 55.6 | 60.7 | 7.2 | 31.9 | 102 |
Bailey et al. (2014) [12] | NCT00528372 | DAPA: 2.5Â mg, 5Â mg, 10Â mg | Naive treatment | 274 | 48.2 | 52.2 | 7.9 | NR | 102 |
Kohan et al. (2013) [13] | NCT00663260 | DAPA: 5Â mg, 10Â mg | OAD | 252 | 65.1 | 67.0 | 8.4 | NR | 104 |
Rosenstock et al. (2012) [14] | NCT00683878 | DAPA: 5Â mg, 10Â mg | PIOG | 420 | 49.5 | 53.5 | 8.4 | NR | 48 |
Wilding et al. (2012) [15] | NCT00673231 | DAPA: 2.5 mg, 5 mg, 10 mg | INS ± OAD | 807 | 47.8 | 59.3 | 8.5 | 33.1 | 48 |
Araki et al. (2017) [16] | NCT02157298 | DAPA: 5 mg | INS ± OAD | 182 | 70.9 | 58.1 | 8.4 | 26.6 | 16 |
Schumm et al. (2015) [17] | NCT01217892 | DAPA: 2.5Â mg, 5Â mg, 10Â mg | MET | 400 | 44.9 | 57.7 | 7.8 | 32.6 | 16 |
Wilding et al. (2013) [18] | NCT01117584 | IPRA: 50Â mg | MET | 134 | 50.7 | 58 | 7.7 | 31.5 | 12 |
Lu et al. (2016) [19] | NCT01505426 | IPRA: 50Â mg | MET | 170 | 45.3 | 53 | 7.7 | 26.8 | 24 |
Han et al. (2018) [20] | NCT02452632 | IPRA: 50 mg | MET + SIT | 139 | 49.6 | 57.5 | 7.9 | 25.8 | 24 |
Fonseca et al. (2013) [21] | NCT01071850 | IPRA: 50Â mg | OAD | 136 | 48.5 | 53 | 8 | 31.5 | 12 |
Min et al. (2017) [22] | NCT01505426 | IPRA: 50Â mg | MET | 82 | 46.3 | 56.1 | 7.6 | 25.8 | 24 |
Kashiwagi et al. (2015) [23] | NCT01057628 | IPRA: 50Â mg | OAD | 129 | 69.8 | 59.4 | 8.3 | 25.5 | 16 |
Gallo et al. (2019) [24] | NCT02033889 | ERTU: 5Â mg, 15Â mg | GLIM | 621 | 46.4 | 56.6 | 8.1 | 31.1 | 104 |
Ji et al. (2015) [25] | NCT01381900 | CANA: 100 mg, 300 mg | MET ± SU | 676 | 53.6 | 56.2 | 8 | 25.7 | 18 |
Bilezikian et al. (2016) [26] | NCT01106651 | CANA: 100Â mg, 300Â mg | OAD | 714 | 55.5 | 63.6 | 7.7 | 31.6 | 104 |
Yale et al. (2014) [27] | NCT01064414 | CANA: 100Â mg, 300Â mg | SU or INS | 269 | 60.6 | 68.5 | 8.0 | 33.0 | 52 |
Rosenstock et al. (2012) [28] | NCT00642278 | CANA: 100Â mg, 300Â mg | MET | 193 | 53.4 | 52.4 | 7.8 | 31.3 | 12 |
Rodbard et al. (2016) [29] | NR | CANA: 100 mg, 300 mg | MET + SIT | 213 | 56.8 | 57.4 | 8.5 | 32.0 | 26 |
Sha et al. (2014) [30] | NCT01483781 | CANA: 300Â mg | OAD | 36 | 86.1 | 62.8 | 7.7 | 29.8 | 12 |
Usiskin et al. (2014) [34] | NCT01081834 NCT01106625 NCT01106677 NCT01106690 | CANA: 100Â mg, 300Â mg | OAD | 2313 | 49.5 | 55.9 | 8 | 32.1 | 26 |
Sone et al. (2020) [31] | NCT02589639 | EMPA: 10 mg, 25 mg | INS ± OAD | 269 | 72.6 | 58.7 | 8.8 | 26.9 | 16 |
Kohler et al. (2018) [35] | NCT01289990 NCT01210001NCT01177813NCT01164501NCT00789035NCT00749190NCT0088511 NCT01011868NCT01947855NCT01193218NCT01370005NCT01306214; NCT01131676 | EMPA: 10Â mg, 25Â mg | OAD | 12,620 | 64.8 | 60.6 | 8.1 | 30.4 | 78 |
Rau et al. (2022) [32] | EudraCT: 2016-000172-19 | EMPA: 10Â mg | OAD | 42 | 81.0 | 62.0 | 7.7 | 31.3 | 3month |
Kullmann et al. (2022) [33] | NCT03227484 | EMPA: 25Â mg | OAD | 40 | 40.0 | 59.9 | 5.7 | 31.5 | 8 |